logo
The anti-ageing Ozempic effect: How weight loss jabs could help you live longer ‘slashing your risk of dying young'

The anti-ageing Ozempic effect: How weight loss jabs could help you live longer ‘slashing your risk of dying young'

The Sun15 hours ago
WEIGHT loss, warding off dementia, 'curing' diabetes and now… anti-ageing powers?
Is there anything the so-called fat jabs can't do?
While a medicine that reverses the clock would be a miracle, we're not quite there, yet.
But scientists hope the 'game-changing miracle' weight loss injections like Ozempic, Wegovy and Mounjaro, could be the next best thing, helping us live longer.
Just last week, a study found that semaglutide - the active ingredient in Ozempic and Wegovy - could "significantly" slash the risk of the brain-robbing disease dementia, in people with type 2 diabetes.
Researchers at Case Western Reserve School of Medicine in Cleveland, Ohio, studied 1.7million American patients with type 2 diabetes over three years.
Originally designed to treat type 2 diabetes, the jabs mimic a gut hormone called GLP-1.
This leads to a reduction in appetite and regulates blood sugar levels.
Now, they are prescribed to help melt fat away, and are taking the nation's waistline by storm.
And new research is showing that these jabs could reduce the risk of various deadly diseases, from heart disease to Alzheimer's and cancer.
They could also prevent deaths from these conditions, according to results of the SELECT trial, published in 2023.
Funded by Ozempic and Wegovy manufacturer Novo Nordisk, it tracked 17,600 people either given the jab, or a placebo, for three years.
Weight Loss Jabs - Pros vs Cons
All of the volunteers taking part were overweight, over the age of 45 and had been diagnosed with cardiovascular disease.
During the trial, 833 people died. But those who were on fat jabs were 19 per cent less likely to die of any cause, and 15 per cent less likely to die a heart-related death.
Levels of inflammation in the body were also reduced, regardless of how much weight was lost.
This is one of the key theories behind why fat jabs may have additional benefits.
Inflammation, triggered by obesity and associated lifestyle choices, is often what drives heart disease and other major causes of death.
'We know that chronic inflammation speeds up ageing,' Dr Amos Ogunkoya, a GP in London, tells Sun Health.
'It causes DNA damage - and that's the reason diabetes and obesity increase the risk of certain cancers and tissue damage.
'The more inflammation you have, the more DNA damage you have.'
Professor Rameen Shakur, a molecular biologist and director of Brighton Integrative Genomics Unit, says: 'We do know that turning down chronic systemic inflammation helps in healthy longevity.'
But he adds: 'Ageing is a complicated soup of systems and signals which is, over time, weakening and decaying the cells that keep our body fit and well.
'It's a multi-dimensional complex, not one thing.
'Ageing involves free radicals, telomeres and general decay. If I have Botox, I won't have wrinkles, but it won't positively affect my heart.
'There's no study that says, 'I took Ozempic and now I'm Benjamin Button'.
'We don't understand if it 'reverses the clock'. But it has additional effects because it reduces calories [eaten].'
What is certain though is that like all medicines, weight loss jabs do come with a range of side effects, most commonly nausea, diarrhoea and constipation.
But there are also more serious risks, including pancreatitis and gastroparesis.
So while there are risks, for those Brits who are overweight and either already living with, or en route to a chronic illness that could shorten their life, doctors agree these jabs have huge potential to improve lives.
So what does the science say? Here's how Ozempic could extend your life…
HEART OF IT
4
LOSING weight has huge benefits on the heart.
'Living with excess weight or obesity can increase the chances of developing cardiovascular disease,' Dr Sonya Babu-Narayan, clinical director at the British Heart Foundation and consultant cardiologist, tells Sun Health.
'The SELECT trial, which involved people with pre-existing cardiovascular disease, found that semaglutide can reduce the risk of dying from cardiovascular disease, or having a heart attack or stroke by around 20 per cent.
'Plus, it was found that semaglutide can reduce the risk of heart attacks and strokes in people with pre-existing cardiovascular disease, even if they didn't lose weight.
'This suggests that the medicines are having other positive effects, such as where fat is stored, and regulation of blood sugar, blood pressure and inflammation.'
Diabetes, high blood pressure and high cholesterol are all associated with obesity, and have a negative impact on the heart and blood vessels.
THE BIG C
OBESITY is the second most common cause of cancer in the UK, behind smoking.
But scientists believe the jabs' influence on inflammation, hormones and chemicals in the blood might add extra protection against cancer.
One study compared 3,200 patients who lost weight with GLP-1 injections with 3,200 who had surgery.
The jabs were 41 per cent more effective at preventing cancer, the researchers from Israel reported in eClinicalMedicine.
Dr Matthew Harris, of the Manchester Cancer Research Centre, added: 'Injectable weight loss medications give a genuinely promising possible option for cancer prevention in the future.'
Another study found diabetics on GLP-1 drugs were less likely to get 13 types of cancer associated with obesity over 15 years, from pancreatic to bowel and womb, than those on other meds.
Everything you need to know about fat jabs
Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases.
Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK.
Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market.
Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year.
How do they work?
The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight.
They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists.
They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high.
Can I get them?
NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics.
Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure.
GPs generally do not prescribe the drugs for weight loss.
Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk.
Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health.
Are there any risks?
Yes – side effects are common but most are relatively mild.
Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea.
Dr Sarah Jarvis, GP and clinical consultant at patient.info, said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.'
Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia.
Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health.
Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines.
MIND MATTERS
STUDIES suggest semaglutide may reduce the risk of Alzheimer's - the most common form of dementia and the leading cause of death in the UK.
One, published in the journal Alzheimer's and Dementia, found that type 2 diabetics had a 40 to 70 per cent reduced risk of Alzheimer's when they were on semaglutide compared to other diabetic drugs.
Another, published in JAMA Neurology, showed a 33 per cent lower risk.
The researchers said it's not clear how the drugs are protecting the brain, but inflammation is thought to play a major role in the development of Alzheimer's.
Dr Amos says: 'Inflammation causes damage to neurons (in the brain).
'It's also quite common for people's Alzheimer's or their cognitive decline to get worse when they're ill because inflammation markers are high.'
A study by Imperial College London also showed that liraglutide (Saxenda) could reduce brain shrinkage in patients already with Alzheimer's, by 50 per cent.
BUT WHAT ABOUT 'OZEMPIC FACE'?
4
WHILE Ozempic-like jabs might have internal anti-ageing benefits, there's a danger they could make you look older.
'' Ozempic face ' is a loss of volume in the face, which can visually make wrinkles look worse,' warns Dr Amos.
'When you lose fat in your face, and your skin doesn't follow, you can look saggy and older.'
Rapid weight loss also means a loss in muscle mass, which helps define a figure and reduce loose skin.
It's also important the more you age to reduce frailty, and protect bones.
Dr Amos recommends weight training while on weight loss jabs.
He says: 'Lots of people are getting Ozempic privately and they're not aware of the side effects of muscle loss and not training or changing their lifestyle.'
'I've slashed my risk of dying young thanks to fat jabs'
FOR Ursula Hirschkorn, 53, the results of Mounjaro have been 'incredible' for her health.
The mum-of-four, from London, saw Mounjaro as her 'best bet' of a future without chronic illness, knowing for years that her weight was a key risk factor.
She tells Sun Health: 'I've got high cholesterol, I had high sugars, I had high blood pressure, and I've got a dementia risk because my mother and my grandmother both had vascular dementia, which is related to weight.
'I wanted to reduce my risk but knew the only way I could do that is to lose weight.
"I had gestational diabetes with my children which means that I'm 50 per cent more likely to develop diabetes over 50.'
Ursula had tried to lose weight but it was always the same story since she began yo-yo dieting as a teenager.
'I have lost weight a couple of times in the past naturally but every time I've put it back on again because the minute I stopped dieting I just started eating again,' she said.
Her tipping point came when her husband Mike, 49, a trainee therapist, lost 4st 7lbs with Mounjaro.
Inspired—and spurred by her own health risks—the freelance content strategist started taking it in February this year.
The side effects, particularly constipation, were 'debilitating', she says.
She stopped the jabs altogether but determined not to give up, she switched providers, landing with VOY, which offers additional support.
Ursula eased back onto Manjaro, and this time, her body adjusted and she suffered no side effects.
She is now on a 7.5 mg dose and has lost 15kg (nearly two stone) so far.
'I'm losing weight quite slowly, but it's the health benefits I'm noticing,' she says.
'I had blood tests at the beginning of the year which showed that I'd actually gone into diabetic range. But after Mounjaro, my blood sugar is completely back to normal, it's not even pre-diabetic.
'I was put on blood pressure tablets but since losing weight, I've been able to come off those.
'I had very high cholesterol and that has fallen a little bit, but I think it's more difficult to tackle.'
Ursula has even become a runner with the help of the NHS Couch to 5K app, and gives tips to others on her TikTok page (@fatgirlswims6)
'When I started, I couldn't have run for a minute without having to stop, sweating and being out of puff. I found walking up the stairs difficult.
'I just recently ran 6km without stopping and felt amazing.
'I go to the gym all the time and I just feel physically so much better, which may be why my mental health has also improved.
'We were on holiday in Malaysia last week and I was able to do active things I couldn't have before, like walking to the top of temples.
'It's amazing.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

US judge blocks Trump administration move to overhaul health agencies
US judge blocks Trump administration move to overhaul health agencies

Reuters

time2 hours ago

  • Reuters

US judge blocks Trump administration move to overhaul health agencies

July 1 (Reuters) - A federal judge on Tuesday blocked the Trump administration from moving forward with plans to overhaul the U.S. Department of Health and Human Services by reorganizing several of its agencies and substantially cutting their workforce. U.S. District Judge Melissa DuBose in Providence, Rhode Island, issued an injunction, opens new tab at the behest of a group of Democratic-led states who challenged a plan HHS Secretary Robert F. Kennedy Jr. announced in March to consolidate agencies and fire 10,000 of the department's employees. The layoffs, in addition to earlier buyout offers and firings of probationary employees, reduced the number of full-time HHS employees to 62,000 from 82,000 and left key offices unable to perform statutory functions, the states alleged. The 19 states that sued, along with the District of Columbia, challenged HHS' implementation of its restructuring plan, which also called for collapsing 28 divisions into 15 and closing half of its 10 regional offices. While the states argued that the entire plan was unlawful, they focused on having DuBose block firings and restructurings at four agencies within HHS, including the U.S. Centers for Disease Control and Prevention and the Office of Head Start. DuBose, an appointee of Democratic President Joe Biden, agreed to do so, saying the states had established a likelihood of proving HHS' action was arbitrary and capricious as well as contrary to law. "The Executive Branch does not have the authority to order, organize, or implement wholesale changes to the structure and function of the agencies created by Congress," she wrote. She ordered HHS to halt mass job cuts and restructurings at the four agencies, which also included the U.S. Food and Drug Administration's Center for Tobacco Products and the Office of the Assistant Secretary for Planning and Evaluation. "Today's order guarantees these programs and services will remain accessible and halts the administration's attempt to sabotage our nation's health care system," New York Attorney General Letitia James, a Democrat, said in a statement. HHS spokesperson Andrew Nixon said it strongly disagreed with the ruling and stands by its decision to "refocus a sprawling bureaucracy that, over time, had become wasteful, inefficient, and resistant to change." The ruling came a day before the terminations of the employees were set to become final. Some of the 10,000 employees had already been reinstated following an outcry over the potential for increased risks to public health. The job cuts were part of the effort by Republican President Donald Trump and the Elon Musk-spearheaded Department of Government Efficiency initiative to shrink the federal government and slash spending. Democratic state attorneys general in a lawsuit, opens new tab filed in May argued that the intended effect of the restructuring was to dismantle key HHS programs. They argued that Kennedy lacked the authority to launch the widespread layoffs and restructuring, which have led to infectious disease lab closures, research being abandoned and partnerships suspended. The states said that the cuts left the CDC unable to meet statutory mandates to investigate diseases due to lab closures and put Head Start centers that support early childhood programs at risk of closing.

What is toasted skin syndrome?
What is toasted skin syndrome?

Medical News Today

time2 hours ago

  • Medical News Today

What is toasted skin syndrome?

Toasted skin syndrome (TSS) is a skin condition that occurs following chronic exposure to moderate heat or infrared radiation. Another name for this condition is 'erythema ab igne', which is Latin for 'redness from fire'.In TSS, repeated direct exposure to heat sources like heat pads, hot water bottles, or heated car seats may cause the skin to become pink and mottled. It may be harder to see on dark skin. Continued exposure to the heat source causes this mottling to darken and take on a reticulated or lace-like cases of TSS eventually resolve after a person stops exposing their skin to the heat source. However, people with severe TSS may experience permanent skin hyperpigmentation. Having TSS also increases the risk of certain types of skin article provides an overview of TSS and outlines the condition's symptoms, causes, and risk factors. We also describe how doctors diagnose and treat TSS, and consider the outlook for people with this skin syndrome (TSS) is a type of skin hyperpigmentation that develops following repeated exposure to moderate heat or infrared radiation. Potential sources of such include:heat pads or hot water bottlesheated car seatsspace heaterslaptops resting on thighsIn TSS, repeated direct contact with a heat source causes damage to the skin's elastic fibers and superficial blood vessels, resulting in hemosiderin deposition and overproduction of the pigment melanin. This process results in a type of mottled or lace-like deposition occurs when red blood cells leak and break down, and iron from those cells leaves a stain in the skin, causing brownish patches. It contributes to the mottled or net-like darkening seen in toasted skin syndrome. Removing the heat source can cause TSS to spontaneously resolve. However, repeated exposure to the heat source can lead to permanent hyperpigmentation. It may also lead to the progression of certain skin cancers, such as:Merkel cell carcinomabasal cell carcinomasquamous cell carcinomaSymptomsAs a 2021 case study explains, the skin lesions associated with TSS may not appear immediately after exposure to a heat source. Instead, they may take several weeks or months to to the American Osteopathic College of Dermatology (AOCD), the first sign of TSS is typically pink, mottled skin. With continued exposure to the heat source, the mottled areas may take on a reticulated or lace-like appearance, with the hyperpigmented areas becoming red, violet, or brown in and risk factorsToasted skin syndrome occurs when the skin comes into direct contact with a moderate-intensity heat source for a sustained period. This causes damage to the skin's elastic fibers and superficial blood vessels, releasing hemosiderin and melanin, which causes the affected area of skin to become hyperpigmented. Historically, TSS was more common among industry workers like bakers and metalworkers, who frequently had close exposure to heat sources. More recent risk factors for TSS include:resting a laptop on the thighsapplying heat pads or hot water bottles to the skinapplying a 'sauna belt' to help treat abdominal obesityusing a heated blanketusing a heated car seatusing a space heaterA 2021 review adds that TSS is more common among women compared to men, and is also more common among people with chronic diagnosing TSS, doctors will consider a person's symptoms alongside any history of heat exposure. In some cases, doctors may take a small sample of the affected skin and examine it under a microscope to look for characteristic signs of TSS. This type of test is called a biopsy, and it can help to rule out other conditions with similar symptoms. According to a 2018 case study, these conditions may include:livedo reticularislivedo racemosacutis marmoratacutis marmorata telangiectatica congenitaTreatmentA 2018 case study notes that TSS typically resolves after a person stops exposing their skin to the heat source. However, since TSS increases the risk of certain skin cancers, individuals who have TSS with skin ulceration or non-healing wounds should undergo a skin biopsy to rule out skin to the AOCD, more advanced cases of TSS may persist for years, and some may even be permanent. Some individuals with permanent hyperpigmentation may have concerns about the appearance of their skin. Treatments that may help to improve the appearance of TSS hyperpigmentation include:the topical treatment '5-fluorouracil'the topical retinoid 'tretinoin'laser therapyOutlookAccording to a 2021 review, TSS usually resolves within weeks or months of removing the heat source, although the rash may become permanent. The review adds that in some cases, TSS may develop into a type of skin cancer, such as:cutaneous squamous cell carcinomaMerkel cell carcinomaheat-induced basal cell carcinomaAnyone who has received a diagnosis of TSS and has continued concerns about their skin can talk to a doctor or dermatologist for further information and skin syndrome (TSS) or 'erythema ab igne' is a type of skin hyperpigmentation that occurs when the skin persistently comes into direct contact with a moderate-intensity heat source, or infrared radiation. In TSS, heat causes the skin's elastic fibers and superficial blood vessels to break down, releasing hemosiderin and melanin. This results in patchy hyperpigmentation that may darken over time and take on a lace-like or mottled diagnose TSS according to a person's symptoms and history of heat exposure. In some cases, doctors may take a skin biopsy to rule out other main treatment for TSS is removal of the heat source, and this method resolves most TSS cases within months. However, severe cases can cause permanent hyperpigmentation, and also increase the risk of certain skin cancers. Anyone who has concerns about this can talk to a doctor or dermatologist for further advice.

AstraZeneca boss ‘wants to shift stock market listing to US'
AstraZeneca boss ‘wants to shift stock market listing to US'

The Guardian

time2 hours ago

  • The Guardian

AstraZeneca boss ‘wants to shift stock market listing to US'

AstraZeneca's chief executive, Pascal Soriot, has reportedly said that he would like to shift the company's stock market listing from the UK to the US. The boss of Britain's most valuable listed company has spoken privately about a preference to move the listing to New York, the Times reported. It added that he had also considered moving the company's domicile. The FTSE 100 company's share price rose by 2.8% on Tuesday, with most of the increase happening after the story was published. A shift in AstraZeneca's listing would deal a major blow to the London Stock Exchange, which has already had to deal with a series of departures by companies seeking higher valuations. Among those who have left the FTSE 100 in recent years are equipment rental company Ashtead, Paddy Power bookmaker owner Flutter Entertainment, building materials supplier CRH and packaging company Smurfit Westrock. A shift by AstraZeneca would almost certainly face opposition by the UK government, although it would not have the power to formally block a move. Labour made life sciences one of its key growth sectors in its industrial strategy published last month. A spokesperson for AstraZeneca declined to comment. The government remains stuck in negotiations with the drug industry, including AstraZeneca, over rebates that pharmaceutical companies must pay on sales of new medicines to the NHS, under a voluntary agreement. Soriot has publicly expressed his frustration over the rejection of AstraZeneca'sbreast cancer drug Enhertu for use in the NHS on cost grounds. Earlier this year, the company, headquartered in Cambridge, caused consternation in government by pulling out of a £450m project to produce vaccines in Speke, Liverpool, while saying that the business case did not make sense without more financial support from government. Soriot has overseen the market value of AstraZeneca more than tripling since he took over in October 2012. The company has overtaken oil company Shell – also seen as a contender for a move to the US – and HSBC, a bank, with a market value of £157bn. Sign up to Business Today Get set for the working day – we'll point you to all the business news and analysis you need every morning after newsletter promotion The US is the world's biggest pharmaceutical market, with by far the highest spending per person on medicines despite having a lower life expectancy than several other countries. UK executives have long complained that their companies are undervalued compared with American counterparts. Soriot has emphasised the company's ambitions to grow in the US. In November, he told investors that 'we want to see even more growth in the US over the next few years as part of our 2030 ambition,' according to a transcript from data company Alphasense. The 'US is, of course, a very important market and that supports innovation, and we will continue to invest to grow fast in this part of the world', Soriot said. The chief executive's pay has increased in line with AstraZeneca's market value. He has been the highest-paid chief executive on the FTSE 100 for two years running, receiving £16.85m for 2023, up from £15.3m in 2022.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store